Literature DB >> 26079646

Relative contributions of severe dopaminergic neuron ablation and dopamine depletion to cognitive impairment.

R Garrett Morgan1, Jeffrey T Gibbs1, Erica J Melief1, Nadia O Postupna1, Emily E Sherfield1, Angela Wilson1, C Dirk Keene1, Thomas J Montine1, Richard D Palmiter2, Martin Darvas3.   

Abstract

Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons and produces a movement disorder and cognitive impairment that becomes more extensive with the duration of the disease. To what extent cognitive impairment in advanced PD can be attributed to severe loss of dopamine (DA) signaling is not well understood. Furthermore, it is unclear if the loss of DA neurons contributes to the cognitive impairment caused by the reduction in DA signaling. We generated genetic mouse models with equally severe chronic loss of DA achieved by either extensive ablation of DA neurons or inactivation of DA synthesis from preserved neurons and compared their motor and cognitive performance. Motor behaviors were equally blunted in both models, but we observed that DA neuron ablation caused more severe cognitive deficits than DA depletion. Both models had marked deficits in cue-discrimination learning. Yet, deficits in cue-discrimination learning were more severe in mice with DA neuron ablation and only mice with DA neuron ablation had drastically impaired performance in spatial learning, spatial memory and object memory tests. These results indicate that while a severe reduction in DA signaling results in motor and cognitive impairments, the loss of DA neurons promotes more extensive cognitive deficits and suggest that a loss of additional factors that depend on DA neurons may participate in the progressive cognitive decline found in patients with PD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; Dementia; Dopamine loss; Neurodegeneration; Parkinson's disease

Mesh:

Substances:

Year:  2015        PMID: 26079646      PMCID: PMC4586402          DOI: 10.1016/j.expneurol.2015.06.013

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  52 in total

1.  Contributions of striatal dopamine signaling to the modulation of cognitive flexibility.

Authors:  Martin Darvas; Richard D Palmiter
Journal:  Biol Psychiatry       Date:  2010-11-11       Impact factor: 13.382

2.  A subpopulation of dopaminergic neurons in rat ventral mesencephalon contains both neurotensin and cholecystokinin.

Authors:  K Seroogy; S Ceccatelli; M Schalling; T Hökfelt; P Frey; J Walsh; G Dockray; J Brown; A Buchan; M Goldstein
Journal:  Brain Res       Date:  1988-07-05       Impact factor: 3.252

Review 3.  Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives.

Authors:  Anthony H V Schapira; C Warren Olanow; J Timothy Greenamyre; Erwan Bezard
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

4.  Dopamine in the hippocampus is cleared by the norepinephrine transporter.

Authors:  Anders Borgkvist; Torun Malmlöf; Kristin Feltmann; Maria Lindskog; Björn Schilström
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-14       Impact factor: 5.176

5.  Vesicular glutamate transport promotes dopamine storage and glutamate corelease in vivo.

Authors:  Thomas S Hnasko; Nao Chuhma; Hui Zhang; Germaine Y Goh; David Sulzer; Richard D Palmiter; Stephen Rayport; Robert H Edwards
Journal:  Neuron       Date:  2010-03-11       Impact factor: 17.173

6.  Dopamine modulates release from corticostriatal terminals.

Authors:  Nigel S Bamford; Siobhan Robinson; Richard D Palmiter; John A Joyce; Cynthia Moore; Charles K Meshul
Journal:  J Neurosci       Date:  2004-10-27       Impact factor: 6.167

7.  Restricting dopaminergic signaling to either dorsolateral or medial striatum facilitates cognition.

Authors:  Martin Darvas; Richard D Palmiter
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

8.  Why am I lost without dopamine? Effects of 6-OHDA lesion on the encoding of reward and decision process in CA3.

Authors:  Aude Retailleau; Cyril Dejean; Benjamin Fourneaux; Xavier Leinekugel; Thomas Boraud
Journal:  Neurobiol Dis       Date:  2013-08-01       Impact factor: 5.996

9.  alpha-Synuclein and neuronal cell death.

Authors:  Mark R Cookson
Journal:  Mol Neurodegener       Date:  2009-02-04       Impact factor: 14.195

Review 10.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

Authors:  C H Williams-Gray; T Foltynie; C E G Brayne; T W Robbins; R A Barker
Journal:  Brain       Date:  2007-05-29       Impact factor: 13.501

View more
  4 in total

1.  Dopamine Deficiency Reduces Striatal Cholinergic Interneuron Function in Models of Parkinson's Disease.

Authors:  Jonathan W McKinley; Ziqing Shi; Ivana Kawikova; Matthew Hur; Ian J Bamford; Suma Priya Sudarsana Devi; Annie Vahedipour; Martin Darvas; Nigel S Bamford
Journal:  Neuron       Date:  2019-07-16       Impact factor: 17.173

Review 2.  Dopamine signaling and myopia development: What are the key challenges.

Authors:  Xiangtian Zhou; Machelle T Pardue; P Michael Iuvone; Jia Qu
Journal:  Prog Retin Eye Res       Date:  2017-06-07       Impact factor: 21.198

3.  Regulation of Cdc42 signaling by the dopamine D2 receptor in a mouse model of Parkinson's disease.

Authors:  Li Ying; Jinlan Zhao; Yingshan Ye; Yutong Liu; Bin Xiao; Tao Xue; Hangfei Zhu; Yue Wu; Jing He; Sifei Qin; Yong Jiang; Fukun Guo; Lin Zhang; Nuyun Liu; Lu Zhang
Journal:  Aging Cell       Date:  2022-04-12       Impact factor: 11.005

4.  Loss of glutamate signaling from the thalamus to dorsal striatum impairs motor function and slows the execution of learned behaviors.

Authors:  Erica J Melief; Jonathan W McKinley; Jonathan Y Lam; Nicole M Whiteley; Alec W Gibson; John F Neumaier; Charles W Henschen; Richard D Palmiter; Nigel S Bamford; Martin Darvas
Journal:  NPJ Parkinsons Dis       Date:  2018-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.